Transcatheter Pulmonary Valve (TPV) Therapy Market is expected to grow at a CAGR of xx% during the forecast period 2022 to 2028. Transcatheter pulmonary valve replacement is a surgical procedure carried in older children and adults with congenital heart disease and have normally at least one previous operation. These valves are delivery by hollow, thin, and long tube system that delivers the transcatheter pulmonary valve into hear without open heart surgery. The Transcatheter Pulmonary Valve (TPV) is a synthetic heart valve created from a cow’s jugular vein valve sewed onto a tiny metal frame. Transcatheter pulmonary valves are delivered through a catheter, which is a thin, hollow, and lengthy tube that is inserted into the heart without the need for open heart surgery while the heart is beating. The transcatheter pulmonary valve is first compressed onto a balloon at the tip of the delivery catheter to deliver into the body, then the balloon in the pulmonary heart valve is inflated to open up the transcatheter pulmonary valve and the catheter is removed from the body, after which it becomes the new pulmonary heart valve. Patients with heart abnormalities who have a failing conduit may benefit from a transcatheter pulmonary valve. The transcatheter pulmonary valve allows patients to postpone the need for additional open heart surgery. Transcatheter Pulmonary Valve (TPV) Therapy Market is being pushed by an increase in the prevalence of comorbidities such as diabetes and cardiovascular illnesses, as well as an increase in the incidence of Congestive Heart Diseases (CHD) among patients of various ages. Transcatheter pulmonary valves are used to extend the functional life of RV-PA conduits, restore pulmonary valve competence, and relieve conduit stenosis in patients without causing regurgitation, making the transcatheter pulmonary valve market profitable over the projected period.